Beaumont Hospital

OncoHost Selected to Present in Oral Minisymposium at American Association of Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Tuesday, March 5, 2024

BINYAMINA, Israel and CARY, N.C., March 5, 2024 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced it will be presenting new results at the American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 5-10, 2024. The oral presentation will feature insights from the company's PROPHETIC trial, to be delivered by Prof. Jarushka Naidoo, consultant medical oncologist at Beaumont Hospital Dublin, professor at the Royal College of Surgeons in Ireland, and co-author of the abstract.

Key Points: 
  • BINYAMINA, Israel and CARY, N.C., March 5, 2024 /PRNewswire/ -- OncoHost , a technology company transforming the approach to precision medicine for improved patient outcomes, today announced it will be presenting new results at the American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 5-10, 2024.
  • Additionally, biological insights related to treatment resistance and immune-related toxicity will be presented.
  • "We are honored to be selected to present our research at the AACR Annual Meeting, highlighting the capabilities of our PROphet® platform in guiding treatment decisions for NSCLC," said Ofer Sharon, MD, CEO of OncoHost.
  • It is a privilege to contribute to this research for the benefit of the cancer community."

Relievant Medsystems Announces Pooled 4-Year Outcomes Validating Long-Term Effectiveness of the Intracept Procedure

Retrieved on: 
Thursday, July 20, 2023

The study includes 94 patients who were successfully treated with the Intracept Procedure and completed four-year study visits.

Key Points: 
  • The study includes 94 patients who were successfully treated with the Intracept Procedure and completed four-year study visits.
  • These results are consistent with multiple clinical trials, including two Level I randomized controlled trials, that demonstrate the long-term effectiveness and durability of the Intracept Procedure.
  • “These latest findings illustrate the long-term effectiveness of the Intracept Procedure and are consistent with previously published results that measured outcomes at five years,” said Tyler Binney, President and CEO of Relievant Medsystems.
  • “More than 10,000 patients have been treated with the Intracept Procedure and we look forward to continuing to partner with physicians to bring patients lasting relief from vertebrogenic pain.”
    For more information on the Intracept Procedure, visit: https://www.relievant.com/intracept/ .

BIOPHYTIS ORGANISES A WEBCAST WITH KEY OPINION LEADERS (KOL) ON THE PHASE 2-3 COVA STUDY RESULTS OF SARCONEOS (BIO101) IN THE TREATMENT OF PNEUMONIA IN COVID-19 PATIENTS AT RISK OF RESPIRAT

Retrieved on: 
Thursday, December 1, 2022

The regulatory development of Sarconeos (BIO101) targeting conditional and emergency use marketing authorisations will start in 2023.

Key Points: 
  • The regulatory development of Sarconeos (BIO101) targeting conditional and emergency use marketing authorisations will start in 2023.
  • As a reminder, the COVA clinical study (identifier clinicaltrials.gov: NCT04472728) is an international, multi-centre, double-blind, placebo-controlled, group-sequential and adaptive two-part study.
  • It is a phase 2-3 study evaluating Sarconeos (BIO101) in patients aged 45 years and older, hospitalised with severe respiratory manifestations of COVID-19.
  • Part 2 of the COVA study is a randomised phase 3 study investigating the safety and efficacy of Sarconeos (BIO101) on respiratory function in patients.

Urovant Sciences® Receives “Best in Category” Award for Abstract Highlighting Investigational Novel Gene Therapy, URO-902, Presented at 2022 International Continence Society Conference

Retrieved on: 
Thursday, September 8, 2022

The award-winning abstract was presented at the 2022 International Continence Society annual meeting on September 8, 2022.

Key Points: 
  • The award-winning abstract was presented at the 2022 International Continence Society annual meeting on September 8, 2022.
  • The 2022 ICS Annual meeting is being held September 7-10, 2022, in a hybrid format with both online and in person participation (Vienna, Austria).
  • The podium presentation at ICS 2022 took place on Thursday, September 8, at 10:20 Central European Time (CET).
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Biophytis announces very promising top line results of its phase 2-3 COVA clinical study in COVID-19-related respiratory failure

Retrieved on: 
Wednesday, September 7, 2022

Sarconeos (BIO101) reduced both the proportion of patients with respiratory failure (12.7% vs 21.5%) and early death (0.8% vs 2.8%).

Key Points: 
  • Sarconeos (BIO101) reduced both the proportion of patients with respiratory failure (12.7% vs 21.5%) and early death (0.8% vs 2.8%).
  • Stanislas Veillet, CEO of Biophytis, said: "The results obtained with Sarconeos (BIO101) in the fight against COVID-19 are very encouraging.
  • As a reminder, the COVA clinical programme (identifier clinicaltrials.gov: NCT04472728) is an international, multi-centre, double-blind, placebo-controlled, group-sequential and adaptive two-part study.
  • Part 2 of the COVA study is a randomised phase 3 study investigating the safety and efficacy of Sarconeos (BIO101) on respiratory function in patients.

American Osteopathic Association installs Ernest R. Gelb, DO, as 126th President

Retrieved on: 
Thursday, July 21, 2022

CHICAGO, July 21, 2022 /PRNewswire/ -- Ernest R. Gelb, DO, FACOFP, an AOA board-certified osteopathic family medicine specialist and geriatrician from Lewes, Delaware, has been installed as the 126th president of the American Osteopathic Association (AOA).

Key Points: 
  • CHICAGO, July 21, 2022 /PRNewswire/ -- Ernest R. Gelb, DO, FACOFP, an AOA board-certified osteopathic family medicine specialist and geriatrician from Lewes, Delaware, has been installed as the 126th president of the American Osteopathic Association (AOA).
  • Dr. Gelb takes office during a time of tremendous growth and expansion for the osteopathic medical profession, which includes more than 178,000 osteopathic physicians (DOs) and osteopathic medical students.
  • He is a past president of the Pennsylvania Osteopathic Medical Association (POMA) and has received multiple awards, including the Pennsylvania Osteopathic Family Physicians Society Family Physician of the Year and the POMA Distinguished Service Award.
  • The American Osteopathic Association (AOA) represents more than 178,000 osteopathic physicians (DOs) and osteopathic medical students; promotes public health; encourages and funds scientific research; serves as the primary certifying body for DOs; and is the accrediting agency for colleges of osteopathic medicine.

Title Alliance, LTD Launches Leadership Academy Summer 2022

Retrieved on: 
Thursday, July 14, 2022

MEDIA, Pa., July 14, 2022 /PRNewswire-PRWeb/ -- The Title Alliance culture actively encourages personal and professional growth. As such, Title Alliance is excited to announce their newest program designed to continually develop their teams, the "Title Alliance Leadership Academy". This program will be offered annually to develop leaders of all levels within the organization and will focus on developing personal and professional skillsets that will strengthen the organization while providing opportunities for the team members to have focused opportunities to become better and stronger leaders. The program will launch in August 2022 with its inaugural class.

Key Points: 
  • Title Alliance is excited to announce the launch of their newest program designed to continually develop their teams, the "Title Alliance Leadership Academy."
  • MEDIA, Pa., July 14, 2022 /PRNewswire-PRWeb/ -- The Title Alliance culture actively encourages personal and professional growth.
  • As such, Title Alliance is excited to announce their newest program designed to continually develop their teams, the "Title Alliance Leadership Academy".
  • Nomination forms for Title Alliance Academy are now available and all nominations are due by July 22, 2022.

Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting

Retrieved on: 
Friday, May 13, 2022

This was a prespecified, 12-week interim analysis of a 48-week multicenter, randomized, double-blind, placebo-controlled, dose-escalation study ( NCT04211831 ).

Key Points: 
  • This was a prespecified, 12-week interim analysis of a 48-week multicenter, randomized, double-blind, placebo-controlled, dose-escalation study ( NCT04211831 ).
  • Treatment-emergent adverse events occurred in 45.5% of patients receiving URO-902 24 mg, 46.2% receiving 48 mg, and 50.0% receiving placebo.
  • We are encouraged by these promising interim safety and efficacy findings for URO-902, said Sef Kurstjens, MD, PhD, Executive Vice President and Chief Medical Officer of Urovant Sciences.
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo, GEMTESA, and the GEMTESA logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902

Retrieved on: 
Monday, March 7, 2022

URO-902 has the potential to be the first gene therapy for patients with OAB.

Key Points: 
  • URO-902 has the potential to be the first gene therapy for patients with OAB.
  • The company plans to present the topline results of the study at the American Urological Association annual meeting being held May 13-16, 2022 in New Orleans, LA.
  • Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for areas of unmet need, with a dedicated focus in Urology.
  • The Companys second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy.

ZOLL TherOx SuperSaturated Oxygen Therapy to Be Highlighted at TCT Scientific Symposium

Retrieved on: 
Thursday, November 4, 2021

ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that its TherOx SuperSaturated Oxygen (SSO2) Therapy will be highlighted at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) annual scientific meeting November 4-6 in Orlando, Florida.

Key Points: 
  • ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that its TherOx SuperSaturated Oxygen (SSO2) Therapy will be highlighted at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) annual scientific meeting November 4-6 in Orlando, Florida.
  • ZOLL TherOx will host product demonstrations and discussions with thought leaders who will share their real-world experiences with SSO2 Therapy in technology suite #CS 5.
  • Our participation in and support of TCT is an essential part of expanding the frontier of STEMI care with SSO2 Therapy, said Neil Johnston, President of ZOLL Circulation.
  • SuperSaturated Oxygen (SSO2) Therapy is the first and only FDA-approved treatment shown to significantly reduce myocardial damage in heart attack patients after percutaneous coronary intervention.